Harvard Bioscience, Inc. (HBIO) AI Stock Analysis

Harvard Bioscience, Inc. specializes in the development, manufacturing, and global distribution of technologies, products, and services for fundamental research, discovery, and pre-clinical testing in pharmaceutical and biotechnology markets. Its portfolio includes cellular and molecular technology instruments such as syringe and peristaltic pump systems, surgical products, infusion systems, and behavior research systems. The company also produces precision measuring instrumentation, including data acquisition systems, micro electrode array solutions, and vitro-systems for extracellular recordings. It distributes products through direct sales, online platforms, catalogs, and distributors to universities, hospitals, research organizations, and biotechnology firms globally.

Between FY2021 and FY2025, annual revenue decreased from $118.9M to $86.5M, reflecting a 5-year revenue CAGR of -3.3%. In FY2025, revenue contracted 8.1% year-over-year, with a gross margin of 53.0% and an operating margin of -0.7%. Net income declined from -$12.4M in FY2024 to -$56.7M in FY2025, resulting in diluted EPS of -$0.87. Free cash flow improved to $5.6M in FY2025 from -$1.8M in FY2024. For the quarter ended June 30, 2026, quarterly revenue increased 11.1% year-over-year, while quarterly earnings declined 80.3%. Trailing twelve month revenue stood at $87.8M with an operating margin of -2.9% and an EPS of -$2.31.

As of June 30, 2026, Harvard Bioscience held $6.5M in cash and short-term investments against $44.2M in total debt, resulting in net debt of $37.7M. Total assets were $76.3M compared to shareholders' equity of $7.4M, representing a debt-to-equity ratio of 5.96. The current ratio stood at 1.87. For FY2025, operating cash flow was $6.7M and capital expenditures were $1.1M. Over the past five years, the company's share count increased by 4.4%.

At the closing price of $8.09 on October 16, 2026, Harvard Bioscience has a market capitalization of $36.8M and an enterprise value of $74.3M. The stock trades at a forward P/E of 15.1x, below the 17.3x median of its US-listed Healthcare peers. Its price-to-sales ratio is 0.4x compared to the peer median of 4.1x, while its EV/EBITDA of 179.3x is well above the peer median of 12.0x. Over the past year, the stock gained 102.2%, outperforming the S&P 500 return of 16.8%, though its 5-year return of -88.2% trails the index return of 83.0%.

Wall Street analyst coverage consists of 1 Buy rating, 1 Hold rating, and 0 Sell ratings. The mean price target of $7.50 is 7.3% below the last closing price of $8.09. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $89.8M and EPS of -$0.38. For the next fiscal year, analysts forecast revenue to grow 5.3% to $94.5M and EPS to improve to $0.65. Harvard Bioscience beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Harvard Bioscience, Inc. (HBIO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: HBIO income statement, HBIO balance sheet, HBIO key metrics, HBIO analyst forecast, HBIO chart. See the HBIO stock overview for the latest quote and news.